Xpharma SRL
Xpharma reported total assets of €3.07m at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Mar 2026).
The score of Xpharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +147 % Total assets +46 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Xpharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 318,475 € | ||||
| Equity | 889,956 € | ||||
| Cash | 104,625 € | ||||
| EBITDA | 127,427 € | ||||
| Total assets | €3.07m |
Filed annual accounts
- Year ended 31 Aug 2025filed on 24 Mar 2026
- Year ended 31 Aug 2024filed on 28 Mar 2025
- Year ended 31 Aug 2023filed on 19 Feb 2024
- Year ended 31 Aug 2022filed on 28 Mar 2023
- Year ended 31 Aug 2021filed on 21 Feb 2022
Xpharma's financial analysis
- Solvency29.0%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Xpharma
Xpharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0663.736.158
- VAT number
- BE0663736158
- Peppol
- Registered · 0208:0663736158 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 03 Oct 2016
- Registered office
- 2870 Puurs-Sint-Amands
- Latest accounts
- 2025 · filed on 24 Mar 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Xpharma (SRL) has been based in Puurs-Sint-Amands since 2016, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 318,475 € and equity of 889,956 €; its revenue is not published. Its solvency stands at 29.0%, below the median of its sector (44.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Xpharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie de Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- GDK Farma Retail sale of pharmaceutical products Grimbergen · balance sheet €3.07m
- Extra-Pharma Retail sale of pharmaceutical products Kapellen · balance sheet €3.06m
- Mouscron Pharma Retail sale of pharmaceutical products Mouscron · balance sheet €3.25m
- E.V.N. Pharma Retail sale of pharmaceutical products Grimbergen · balance sheet €3.28m
- Van Nuffel - de Vriendt Retail sale of pharmaceutical products Beveren-Kruibeke-Zwijndrecht · balance sheet €2.84m
- Les Pharmacies de Gare Retail sale of pharmaceutical products Brussels · balance sheet €2.73m
- Apotheek Van den Broeck Riet Retail sale of pharmaceutical products Ranst · balance sheet €2.67m
Frequently asked questions about Xpharma
What is the revenue of Xpharma?
Xpharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Xpharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0663736158 for Xpharma, if the company is VAT-registered. Its company number (CBE) is 0663.736.158.
Where is the registered office of Xpharma?
According to the CBE register, the registered office of Xpharma is in 2870 Puurs-Sint-Amands.
What is the equity of Xpharma?
At the close of the 2025 financial year, the equity of Xpharma amounts to 889,956 €, a solvency of 29.0% of total assets.
Who manages Xpharma?
The register lists 1 active mandates at Xpharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Xpharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →